Posted by Michael Wonder on 17 Feb 2026
Acrotech Biopharma announces FDA approval of Adquey (difamilast 1%) ointment for the treatment of mild to moderate atopic dermatitis
13 February 2026 - Acrotech Biopharma, in collaboration with Otsuka, today announces that the US FDA has approved the new drug application for Adquey (difamilast 1%) ointment, for the topical treatment of mild to moderate atopic dermatitis in adults and paediatric patients aged 2 and older.
Adquey is a novel, non-steroidal, topical phosphodiesterase 4 inhibitor.
